Loading
Life sciences · Journal article
Microbiology · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The advent of cystic fibrosis transmembrane conductance regulator modulators has revolutionized cystic fibrosis (CF) care by restoring epithelial ion transport and improving airway physiology in people with CF. These therapies reduce infection burden, especially from Pseudomonas aeruginosa, through enhanced mucociliary clearance and immune responses. Yet, P. aeruginosa often persists, raising concerns about microbial adaptation. Emerging evidence suggests that modulator-altered airways impose novel selective pressures, favouring mutations in genes linked to biofilm formation, iron metabolism and immune evasion. This may drive the emergence of strains adapted to a ‘hybrid’ airway; neither fully CF-like nor fully healthy. Such adaptations could potentially increase transmissibility or virulence, with implications beyond the CF population. Understanding how pathogens evolve under modulator pressure is essential in this new treatment era. Continued surveillance of microbial dynamics will be key to anticipating shifts in infection risk and informing future clinical and public health strategies.